We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Human Genome Sciences, Inc. (MM) | NASDAQ:HGSI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.24 | 0 | 01:00:00 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare company, said Friday it has completed its acquisition of Human Genome Sciences (HGSI) for 3.6 billion dollars on an equity basis, or $3 billion net of cash and debt.
MAIN FACTS:
-All outstanding shares of HGS were acquired for $14.25 per share in cash.
-Subsequent offering period for GSK's tender offer for HGS shares expired at 2100 GMT, on Aug. 2.
-Glaxo shares closed in London Thursday at 1487 pence valuing the company at 74.16 billion pounds.
-Write to Ian Walker at ian.walker@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Human Genome Sciences Chart |
1 Month Human Genome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
